2026-04-29T04:10:07Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/182552024-11-28T15:49:14Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16958col_20.500.12105_16988

00925njm 22002777a 4500 dc Martínez-Trufero, Javier author De Sande-González, Luis Miguel author Luna, Pablo author Martin-Broto, Javier author Álvarez, Rosa author Marquina, Gloria author Diaz-Beveridge, Roberto author Poveda, Andrés author Cano, Juana María author Cruz-Jurado, Josefina author López Pousa, Antonio author Vaz Salgado, María Angeles author Valverde-Morales, Claudia M. author Sevilla, Isabel author Martínez-García, Jerónimo author Rubio-Casadevall, Jordi author De Juan, Ana author Carrasco, Juan Antonio author Moura, David S. author Gurruchaga-Sotes, Ibon author Gutiérrez, Antonio author 2021-02-14 The aim of this study was to identify an easily reliable prognostic score that selects the subset of advanced soft tissue sarcoma (ASTS) patients with a higher benefit with trabectedin in terms of time to progression and overall survival. A retrospective series of 357 patients with ASTS treated with trabectedin as second- or further-line in 19 centers across Spain was analyzed. First, it was confirmed that patients with high growth modulation index (GMI > 1.33) were associated with the better clinical outcome. Univariate and multivariate analyses were performed to identify factors associated with a GMI > 1.33. Thus, GEISTRA score was based on metastasis free-interval (MFI ≤ 9.7 months), Karnofsky < 80%, Non L-sarcomas and better response in the previous systemic line. The median GMI was 0.82 (0–69), with 198 patients (55%) with a GMI < 1, 41 (11.5%) with a GMI 1–1.33 and 118 (33.1%) with a GMI > 1.33. The lowest GEISTRA score showed a median of time-to-progression (TTP) and overall survival (OS) of 5.7 and 19.5 months, respectively, whereas it was 1.8 and 3.1 months for TTP and OS, respectively, for the GEISTRA 4 score. This prognostic tool can contribute to better selecting candidates for trabectedin treatment in ASTS. http://hdl.handle.net/10668/4498 http://hdl.handle.net/20.500.12105/18255 33672857 10.3390/cancers13040792 2072-6694 Cancers Trabectedin Sarcoma Growth modulation index Prognostic score L-sarcoma GEISTRA Spain Advanced soft tissue sarcomas Trabectedina Pronóstico Liposarcoma Leiomiosarcoma España A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study